Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial - Concepedia

Concepedia

Publication | Closed Access

Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial

138

Citations

34

References

2009

Year

Ian D. Davis, Ben Brady, Richard Kefford, Michael Millward, Jonathan Cebon, Birte K. Skrumsager, Ulrik Mouritzen, Lasse Tengbjerg Hansen, Kresten Skak, Dorthe Lundsgaard,

Clinical Cancer Research

Abstract

rIL-21 administered at 30 microg/kg/d in 5-day cycles every second week is biologically active and well tolerated in patients with metastatic melanoma. Confirmed responses, including one CR, were observed.

References

	Year	Citations

Page 1